Antigen News and Research

RSS

Microbial ecosystems influence success of cancer checkpoint immunotherapy

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies.

9 Mar 2026

Protein aggregates in the liver may protect against alcohol-induced damage

Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.

9 Mar 2026

$Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia$

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them.

9 Mar 2026

Single dose of CAR-astrocyte therapy halves amyloid levels in mice brains

The new generation of Alzheimer's disease drugs - the first proven to change the course of the disease - typically extend independent living for patients by 10 months.

6 Mar 2026

A review of methionine dependency in modern cancer therapy

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.

6 Mar 2026

Researchers identify TRIM13 protein as key driver of immune suppression in sepsis

Dendritic cells (DCs) are increasingly recognized as important contributors to sepsis-associated immune dysfunction.

4 Mar 2026

Study identifies a promising strategy to treat brain metastases

A new study from researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung cancer.

2 Mar 2026

Non-invasive immune monitoring via bandage-like microneedle patches

Researchers at The Jackson Laboratory (JAX), in collaboration with the Massachusetts Institute of Technology (MIT), have developed the first bandage-like microneedle patch that can sample the body's immune responses painlessly from the skin.

2 Mar 2026

Targeted fluorescent probes for high-contrast cancer detection

Cancer is a universal issue that affects uncountably many people around the world. Many will turn to surgery in the hope that a surgeon will be able to completely remove a tumor, leaving healthy tissues unaffected. Various tools and techniques have been developed over the years to improve the way these surgeries are performed, and visual imaging methods such as glowing dyes have proven to be very useful.

2 Mar 2026

New biomarkers for targeted gastric therapy

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity compared with earlier agents, most patients either fail to respond initially or eventually develop resistance.

26 Feb 2026

Ultra-sensitive CAR T cells target solid tumors

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors.

26 Feb 2026

Next-generation CAR T therapy offers hope but faces clinical challenges

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment."

25 Feb 2026

Researchers uncover vulnerabilities in elusive HIV reservoir clones

A new study has overcome a long-standing challenge-how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease difficult to cure.

24 Feb 2026

Ochsner MD Anderson Cancer Center delivers Louisiana’s first TIL therapy for melanoma

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced cancer treatment, as the first institution in Louisiana to provide an adult patient with tumor-infiltrating lymphocytes (TIL) therapy for advanced melanoma.

23 Feb 2026

Optimized costimulatory domains boost tumor killing in CAR NK cells

Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, such as 2B4 and DAP12.

20 Feb 2026

Distinct gut toxicity patterns emerge with targeted cancer treatments

A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled "Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection."

20 Feb 2026

Genetic mismatch identified as major risk factor in cord blood transplantation

A Japanese study of more than 7,400 patients has identified a genetic mismatch that sharply increases the risk of severe acute graft-versus-host disease (GVHD) following umbilical cord blood transplantation.

20 Feb 2026

Remote-controlled CAR T cells offer safer cancer therapy

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers.

19 Feb 2026

Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk

An individualized neoantigen mRNA vaccine was tested in patients with early-stage triple-negative breast cancer and showed feasibility, safety, and strong T cell immune responses. Long-term follow-up suggested durable immune memory with encouraging relapse-free outcomes, though controlled trials are needed to confirm clinical benefit.

19 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026